We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
+25.95%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.16B
AUM Growth
+$665M
Cap. Flow
-$4.87M
Cap. Flow %
-0.12%
Top 10 Hldgs %
57.45%
Holding
61
New
12
Increased
2
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$121M
2
AURA icon
Aura Biosciences
AURA
+$68.2M
3
TRAX
First Tracks Biotherapeutics
TRAX
+$54.1M
4
AVTX icon
Avalo Therapeutics
AVTX
+$36M
5
EDIT icon
Editas Medicine
EDIT
+$32.5M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$170M
2
ABVX
Abivax
ABVX
+$53.6M
3
FULC icon
Fulcrum Therapeutics
FULC
+$40.3M
4
TNGX icon
Tango Therapeutics
TNGX
+$35.8M
5
RVMD icon
Revolution Medicines
RVMD
+$34.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.82%
2 Financials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$9.89B
$801M 19.24%
6,007,834
-473,251
-7% -$53.6M
TNGX icon
2
Tango Therapeutics
TNGX
$3.94B
$284M 6.82%
9,081,201
-1,449,870
-14% -$35.8M
CGON icon
3
CG Oncology
CGON
$6.59B
$261M 6.27%
3,670,206
– –
COGT icon
4
Cogent Biosciences
COGT
$6.02B
$188M 4.52%
4,854,436
-92,458
-2% -$3.23M
IMVT icon
5
Immunovant
IMVT
$8.51B
$172M 4.13%
4,457,988
– –
SYRE icon
6
Spyre Therapeutics
SYRE
$7.97B
$169M 4.06%
1,900,582
– –
DNTH icon
7
Dianthus Therapeutics
DNTH
$5.92B
$163M 3.93%
1,676,624
– –
MIRM icon
8
Mirum Pharmaceuticals
MIRM
$5.94B
$124M 2.99%
1,062,049
– –
ZLAB icon
9
Zai Lab
ZLAB
$2.93B
$117M 2.8%
+6,137,627
New +$121M
AMLX icon
10
Amylyx Pharmaceuticals
AMLX
$3.87B
$112M 2.7%
6,243,812
– –
GLUE icon
11
Monte Rosa Therapeutics
GLUE
$1.14B
$112M 2.69%
4,622,151
– –
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.51B
$110M 2.65%
11,020,968
– –
VOR icon
13
Vor Biopharma
VOR
$1.34B
$104M 2.51%
5,673,078
– –
TYRA icon
14
Tyra Biosciences
TYRA
$1.49B
$104M 2.49%
3,248,980
– –
DYN icon
15
Dyne Therapeutics
DYN
$4.68B
$103M 2.46%
4,615,144
– –
IRON icon
16
Disc Medicine
IRON
$3.07B
$98.1M 2.36%
1,341,862
– –
RLAY icon
17
Relay Therapeutics
RLAY
$4.11B
$80M 1.92%
4,273,356
– –
SVRA icon
18
Savara
SVRA
$1.08B
$76.2M 1.83%
12,362,205
– –
AURA icon
19
Aura Biosciences
AURA
$767M
$67.7M 1.63%
+9,533,333
New +$68.2M
RVMD icon
20
Revolution Medicines
RVMD
$44.6B
$63.8M 1.53%
340,899
-235,574
-41% -$34.4M
TRAX
21
First Tracks Biotherapeutics
TRAX
$1.5B
$58.3M 1.4%
+2,895,304
New +$54.1M
KOD icon
22
Kodiak Sciences
KOD
$2.37B
$56.3M 1.35%
1,445,538
– –
AVTX icon
23
Avalo Therapeutics
AVTX
$1.05B
$55.8M 1.34%
3,017,120
+2,278,737
+309% +$36M
LBRX
24
LB Pharmaceuticals
LBRX
$1.54B
$47M 1.13%
1,447,310
-392,179
-21% -$11.5M
IPSC icon
25
Century Therapeutics
IPSC
$366M
$43.4M 1.04%
17,754,430
– –
1
2 3

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return

TCG Crossover Management's Q2 2026 Portfolio in Review

As of Q2 2026, TCG Crossover Management held 61 positions worth $4.16B, up 19% from $3.5B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

TCG Crossover Management's Q2 2026 filing shows 12 new, 2 increased, 9 reduced and 7 closed positions. Its largest new stake was Zai Lab: 6,137,627 shares worth $117M. The largest sale was Centessa Pharmaceuticals, an estimated $170M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • TCG Crossover Management's largest Q2 2026 buy was Zai Lab: 6,137,627 shares worth $117M.
  • TCG Crossover Management added most to Avalo Therapeutics in Q2 2026, an estimated $36M increase.
  • TCG Crossover Management's biggest Q2 2026 reduction was Abivax, cutting an estimated $53.6M.
  • TCG Crossover Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $170M.
  • TCG Crossover Management's ten largest holdings make up 57% of its $4.16B portfolio in Q2 2026.
  • TCG Crossover Management opened 12 new positions and closed 7 in Q2 2026.
  • TCG Crossover Management's portfolio value rose 19% quarter-over-quarter to $4.16B.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.